Protagenic Therapeutics, Inc. (PTIX)
Automate Your Wheel Strategy on PTIX
With Tiblio's Option Bot, you can configure your own wheel strategy including PTIX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PTIX
- Rev/Share 0.0
- Book/Share -0.1688
- PB -25.2326
- Debt/Equity 0.0
- CurrentRatio 0.8618
- ROIC 61.2483
- MktCap 3699444.0
- FreeCF/Share -6.9294
- PFCF -1.0204
- PE -0.4252
- Debt/Assets 0.0
- DivYield 0
- ROE -8.6063
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
Published: July 30, 2025 by: MCAP MediaWire
Sentiment: Neutral
NEW YORK, NY and SANTA BARBARA, CA, July 30, 2025 – PRISM MediaWire – Protagenic Therapeutics, Inc. (Nasdaq: PTIX) (the “Company”) today announces that on July 18, 2025, the Japanese Patent Office granted Patent JP 7714571B, a patent which runs until March 31, 2041.
Read More
Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK and SANTA BARBARA, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) (the “Company”) today announces that on July 18, 2025, the Japanese Patent Office granted Patent JP 7714571B, a patent which runs until March 31, 2041.
Read More
Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") announced today that warrant exchanges and exercises over the last four trading days have generated $3.1 million in cash. The proceeds will fund working-capital needs and advance the Company's peptide-based drug candidates for stress-related and central-nervous-system disorders.
Read More
Gold Gains Over 1%; Protagenic Therapeutics Shares Spike Higher
Published: May 19, 2025 by: Benzinga
Sentiment: Neutral
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 150 points on Monday.
Read More
Protagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic Disorders
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY AND SANTA BARBARA, CA / ACCESS Newswire / May 19, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") and Phytanix Bio Inc. have entered into a definitive share exchange agreement pursuant to which the two entities will combine in an all-stock transaction (the "Combination"). The combined entity, to be called Phytanix, Inc., will bring together two pipelines focused on stress-related and CNS disorders, five preclinical assets and one clinical-stage asset.
Read More
About Protagenic Therapeutics, Inc. (PTIX)
- IPO Date 2021-04-27
- Website https://www.protagenic.com
- Industry Biotechnology
- CEO Garo H. Armen
- Employees 1